Not Tagged
pfizer
[]
at #gi23, learn more about an ongoing phase 1 pk, safety, and tolerability study evaluating a selective tam kinase inhibitor as a single agent or combination regimen in patients w/ advanced or metastatic solid tumors tps270 
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ